Date of Award


Document Type

Open Access Thesis

Degree Name

Master of Medical Science (MMSc)

First Advisor

F. Perry Wilson, MD, MSCE


Metabolic syndrome is a critical risk factor for the development of type 2 diabetes mellitus and cardiovascular disease, two of the leading causes of death in the United States. With over one third of the adult population currently affected, this syndrome poses a serious health and economic burden. Lifestyle modification is the primary treatment, however only 50% maintain adherence. A single pharmacological therapy such as canagliflozin may overcome this lack of treatment adherence. Our purpose is to establish a difference between canagliflozin 300 milligrams daily plus lifestyle modification education and lifestyle modification education alone for the remission of metabolic syndrome in nondiabetic adults after one year. We will conduct a double-blind, randomized placebo-controlled trial in order to assess for this primary endpoint. This study has the capability to improve the current treatment of metabolic syndrome and potentially prevent the development of type 2 diabetes mellitus and cardiovascular disease.

Open Access

This Article is Open Access